HonCode

Go Back   HER2 Support Group Forums > Articles of Interest
Register Gallery FAQ Members List Calendar Search Today's Posts Mark Forums Read

Reply
 
Thread Tools Display Modes
Old 10-31-2013, 09:29 PM   #1
'lizbeth
Senior Member
 
'lizbeth's Avatar
 
Join Date: Apr 2008
Location: Sunny San Diego
Posts: 2,214
Post Status of AE37 vaccine

Generex Announces Podium Presentation on Antigen Express Cancer Vaccine Strategy

2013 Immunotherapies Congress in Boston


WORCESTER, Mass. and TORONTO, Aug. 13, 2013 /PRNewswire/ -- Generex Biotechnology Corporation (www.generex.com) (OTCBB: GNBT) today announced that Dr. Eric von Hofe, Ph.D., President of its wholly-owned subsidiary, Antigen Express, Inc. (www.antigenexpress.com), will be making a presentation at the Emerging Cancer Immunotherapies and Vaccines conference that is being held as part of the 2013 Immunotherapies Congress in Boston August 13-14. The conference brings together leaders in both academia and industry, focusing on next-generation targets and strategies for cancer immunotherapy. Using lessons learned from early cancer vaccines and immunotherapeutics, a new wave of programs are underway that promise improved efficacy and safety over a wider range of cancers. Emerging Cancer Immunotherapies and Vaccines will examine new targets and strategies in this space, along with important studies in preclinical development associated with developing these programs into successful drug products.
The presentation, entitled 'Augmenting Antigen-Specific CD4+ T Cell Activation in Cancer Immunotherapy', will highlight the significance of activating this particular cell type in the context of immunotherapy strategies designed to inhibit immune suppressive effects. Examples of this strategy include PD-1 inhibitors and the recently approved CTLA4 inhibitor Yervoy®.
"While some approaches focus on taking the brakes off the immune system in a non-specific way, our strategy with AE37 is to step on the gas to specifically target tumor cells," commented Dr. von Hofe. A wealth of accumulating evidence from both the clinic and research laboratories underscores the importance of specifically activating CD4+ T cells for effective cancer immunotherapy.
The presentation coincides with a conference call on August 14 featuring members of the Antigen Express Scientific Advisory Board, key opinion leaders who will discuss recent advances in cancer immunotherapy relevant to the positioning of the Antigen Express lead product AE37 as well as the proprietary Ii-Key technology platform upon which it is based.
Antigen Express was founded on a proprietary technology platform capable of generating a robust response against nearly any target one desires the immune system to recognize. The most advanced compound based on this platform, AE37, is currently in a late Phase II clinical trial to establish efficacy in preventing relapse in patients who have had breast cancer. Results from an interim analysis conducted in October of 2011 were highly encouraging. Based on those results, the Company has been encouraged to submit a Phase III protocol by the FDA. Primary efficacy data is anticipated this fall.
'lizbeth is offline   Reply With Quote
Reply

Thread Tools
Display Modes

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On

Forum Jump


All times are GMT -7. The time now is 03:54 AM.


Powered by vBulletin® Version 3.8.7
Copyright ©2000 - 2024, vBulletin Solutions, Inc.
Copyright HER2 Support Group 2007 - 2021
free webpage hit counter